Competition Commission refers cancer drugmaker to tribunal
The commission wants a maximum fine imposed on the company for excessive pricing
13 December 2024 - 16:37
The Competition Commission has referred international drug manufacturer Celgene Corporation and its subsidiary Celgene Logistics for prosecution by the Competition Tribunal for excessive pricing of a bone marrow cancer treatment drug, Revlimid.
The commission has asked the tribunal to impose a maximum penalty against Celgene for the alleged contravention of the Competition Act...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.